Oncology Companion Diagnostic Market to Reach USD 14.65 Billion by 2035, Driven by Precision Oncology Expansion
核心洞察
The global oncology companion diagnostic market was valued at USD 5.09 billion in 2025 and is projected to reach USD 14.65 billion by 2035, growing at a CAGR of 11.09%.
North America held the largest revenue share at over 42.86% in 2025, with the U.S. market alone valued at USD 2.17 billion, fueled by FDA regulatory leadership in precision oncology.
Non-small cell lung cancer (搜索) (NSCLC) dominated the market with approximately 31% share in 2025, while breast cancer (搜索) represents the fastest-growing cancer type segment.
The global oncology companion diagnostic market is poised for substantial growth over the next decade, with a projected valuation of USD 14.65 billion by 2035, according to a new report from SNS Insider. The market, which stood at USD 5.09 billion in 2025, is expected to expand at a compound annual growth rate (CAGR) of 11.09% from 2026 to 2035, reflecting the accelerating integration of precision medicine into mainstream oncology practice.
Oncology companion diagnostics are in vitro tests evaluated in conjunction with targeted cancer therapies to identify patients most likely to respond to treatment, thereby guiding personalized therapeutic decisions. As molecular profiling and biomarker testing become increasingly essential at the point of diagnosis, demand for these advanced diagnostic solutions continues to rise across hospitals, cancer centers, and diagnostic laboratories worldwide.
Targeted Therapy Pipeline Drives Market Momentum
The market expansion is closely tied to the rapid development of targeted oncology therapies and biomarker-driven drug development. According to the SNS Insider report, more than 1,000 oncology drugs are currently in clinical development, with many targeting biomarker-defined patient populations. This has elevated companion diagnostics to a critical component of both regulatory approval and commercialization strategy. Growing regulatory requirements for co-approved diagnostics alongside targeted therapies are further reinforcing adoption trends globally.
Technology Landscape: PCR Leads, NGS Surges
Polymerase chain reaction (PCR) dominated the oncology companion diagnostic market in 2025, a position attributed to its high accuracy, rapid turnaround time, cost-effectiveness, and widespread use in identifying established cancer biomarkers. However, next-generation sequencing (NGS) is emerging as the fastest-growing technology segment, with a projected CAGR of approximately 12.64% during the forecast period. This growth is driven by increasing demand for comprehensive genomic profiling and multi-gene testing capabilities on a global scale.
In terms of product categories, assay kits and reagents held the largest market share in 2025, supported by recurring demand for testing consumables, rising cancer diagnostic volumes, and expanding use of biomarker-based treatment selection. The "others" category, which includes outsourced specialized diagnostic testing and reference laboratory services, is identified as the fastest-growing product segment.
Cancer Type Analysis: NSCLC Dominates, Breast Cancer (搜索) Accelerates
Non-small cell lung cancer (搜索) (NSCLC) accounted for approximately 31% of the oncology companion diagnostic market in 2025, the largest share among all cancer types. This dominance reflects the high prevalence of actionable genetic mutations in NSCLC, extensive biomarker testing requirements, and the availability of numerous targeted therapies for this indication. Breast cancer (搜索) is identified as the fastest-growing segment during the forecast period, fueled by the expanding global adoption of genomic testing.
End-User Dynamics
Pharmaceutical and biopharmaceutical companies commanded approximately 46.27% of the market in 2025, driven by significant investments in targeted drug development, biomarker discovery programs, and companion diagnostic co-development activities. Contract research organizations (CROs) are projected to experience strong growth, supported by the rising outsourcing of clinical trial services worldwide.
Regional Market Performance
North America held the largest revenue share at over 42.86% in 2025, with the United States representing approximately 82.5% of North American revenues. The U.S. oncology companion diagnostic market was valued at approximately USD 2.17 billion in 2025 and is expected to reach approximately USD 6.24 billion by 2035, growing at a CAGR of approximately 11.12%. The FDA's regulatory leadership in precision oncology, including the establishment of the companion diagnostic approval pathway through seminal co-approvals, underpins this market strength.
Europe represented an estimated USD 1.47 billion market in 2025, projected to reach USD 4.07 billion by 2035 at a CAGR of 10.72%. Key national markets—Germany, France, the UK, Italy, and Spain—benefit from universal healthcare cancer care programs, academic oncology centers, and a progressive EMA regulatory framework for companion diagnostic co-approval.
The Asia Pacific region is growing at the fastest CAGR of 12.34%, driven by increasing healthcare infrastructure investment, rising adoption of precision oncology, and evolving regulatory scenarios in China, India, Japan, and South Korea.
Recent Industry Developments
In 2025, Roche launched an advanced companion diagnostic assay designed to detect novel biomarker signatures across multiple oncology indications, enabling detailed molecular tumor profiling from a single tissue sample to support first-line targeted therapy selection and inform subsequent treatment options.
In 2024, Thermo Fisher Scientific expanded the coverage of its Oncomine Dx Target Test, an NGS-based companion diagnostic, to include more actionable genomic alterations in NSCLC and other solid tumor types, advancing the clinical utility of comprehensive NGS companion diagnostic testing beyond single-gene PCR alternatives.
Key Market Players
Leading companies identified in the report include F. Hoffmann-La Roche Ltd., QIAGEN N.V. (搜索), Thermo Fisher Scientific Inc. (搜索), Illumina, Inc., Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Guardant Health, Inc., Exact Sciences Corporation, Myriad Genetics, Inc., NeoGenomics, Inc., Foundation Medicine, Inc., Sysmex Corporation, Natera, Inc., Invivoscribe, Inc., Danaher Corporation (Cepheid), PERSONALIS, Inc., Adaptive Biotechnologies Corporation, Biocartis Group NV, and Genomic Health, Inc. (Exact Sciences).